Skye Bioscience, Inc.
OTC:SKYE
4.12 (USD) • At close September 8, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.299 | 0.124 | 0.115 | 0.034 | 0.002 |
| Gross Profit
| -0.299 | -0.124 | -0.115 | -0.034 | -0.002 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 18.702 | 5.819 | 6.012 | 2.931 | 1.944 |
| General & Administrative Expenses
| 17.726 | 7.852 | 6.095 | 4.916 | 4.345 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 |
| SG&A
| 17.726 | 7.728 | 6.095 | 4.916 | 4.345 |
| Other Expenses
| -0.299 | 0.001 | -0.116 | 0.001 | 0 |
| Operating Expenses
| 36.129 | 13.548 | 11.991 | 7.848 | 6.289 |
| Operating Income
| -36.427 | -13.672 | -12.106 | -7.848 | -6.289 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 9.87 | -23.969 | -7.368 | -0.672 | -0.27 |
| Income Before Tax
| -26.557 | -37.641 | -19.475 | -8.52 | -6.559 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.01 | 0.004 | 0.007 | 0.002 | 0.002 |
| Net Income
| -26.567 | -37.645 | -19.482 | -8.522 | -6.561 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.73 | -5.37 | -9.82 | -5.24 | -7.11 |
| EPS Diluted
| -0.73 | -5.37 | -10 | -5.24 | -7.46 |
| EBITDA
| -25.509 | -36.611 | -18.575 | -7.717 | -5.851 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 |